News | Proton Therapy | October 23, 2015

Breast Cancer Patient Undergoes First Cone Beam CT-Supported Proton Therapy Treatment

Imaging modality integrated with IBA’s Proteus One system allows more precise patient positioning

IBA, Proteus One, compact proton therapy system, first cone beam CT-supported treatment, Willis-Knighton Cancer Center

Image courtesy of IBA

October 23, 2015 — IBA announced that a breast cancer patient at Willis-Knighton Cancer Center has received the first U.S. Food and Drug Administration (FDA)-approved compact proton therapy treatment with cone beam computed tomography (CBCT). The treatment was completed using IBA’s Proteus One system.

Rather than scheduling one CT image on a weekly basis, the volumetric imaging modality CBCT offers the possibility to make qualitative images on a more frequent basis before or after the actual treatment, putting proton therapy on the threshold of adaptive treatment. Furthermore, it enhances the patient positioning precision, improving the global treatment quality. IBA has made the CBCT imaging modality available for different configurations and is the first and only company to have obtained FDA approval on a CBCT solution for a compact treatment system. The CBCT solution is fully integrated with IBA’s imaging platform adaPTinsight to offer fast 6-D corrections of patient positioning.

Clinical staff at the Willis-­Knighton Cancer Center selected a breast cancer patient to be the first for this newly commissioned imaging modality. It allowed for a very fluent patient setup, adding no more than a couple of minutes to the time spent by the patient in the treatment room. Willis-­Knighton clinicians believe that this superior verification tool will be an asset to improve and expand proton therapy treatment for head and neck, pancreatic and breast cancer patients in particular.

Lane Rosen, M.D., medical director of radiation oncology at the Willis-­Knighton Cancer Center, commented: “Nobody doubts proton therapy’s potential for ultimate precision and healthy tissue sparing, but on the spot verification remained a liability to fully leverage this accuracy. Now that our Proteus One installation features CBCT imaging, we can further enhance and expand proton therapy treatment for indications demanding the utmost precision.”

Greg Sonnenfeld, Willis­-Knighton’s cancer center administrator, commented: “From the moment we decided on the purchase of our Proteus One, it was indisputable that CBCT facilities would be added to our proton therapy solution. IBA did a wonderful job with the image quality and workflow so we are still able to maintain patient care and throughput while having superior imaging.”

For more information: www.iba-worldwide.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...